Egypt’s FRA Blocks Speed Medical’s EGP 600 Million Capital Increase Over Funding Plan Concerns
Egypt’s Financial Regulatory Authority (FRA) has rejected Speed Medical’s request to proceed with a proposed capital increase that would have nearly tripled its paid-in capital to EGP 932.7 million, after determining that the feasibility study did not provide sufficient justification for how the new funds would be used.
The decision interrupts a plan approved by Speed Medical’s board only days earlier to increase issued and paid-in capital from EGP 332.74 million to EGP 932.74 million, through an EGP 600 million cash subscription.
The proposed increase would have involved issuing 3 billion new shares at a nominal value of EGP 0.20 each, with existing shareholders given subscription rights that could be traded separately from the original shares.
FRA questions the case for EGP 600 million in fresh capital
At the heart of the regulator’s decision is not simply the size of the capital increase, but whether Speed Medical had demonstrated a sufficiently clear economic case for raising the money.
According to the FRA’s assessment, the feasibility study submitted by the healthcare company did not provide adequate justification for the proposed use of the EGP 600 million proceeds.
That effectively prevents the company from moving ahead with the transaction in its current form.
The decision highlights the scrutiny facing listed companies seeking significant cash capital increases, particularly when existing shareholders are being asked to inject substantial new funds.
Capital would have almost tripled
Speed Medical’s proposal was sizeable relative to its existing equity base.
Alongside the planned increase in issued capital, the board had proposed raising the company’s authorized capital from EGP 520 million to EGP 1.5 billion.
The issued and paid-in capital would have increased by around 180%, from EGP 332.74 million to EGP 932.74 million.
Speed Medical’s board approved the feasibility study and the proposed capital changes on September 13, with plans to refer them to an extraordinary general meeting.
The FRA’s rejection now puts that process on hold unless the company revises its proposal and provides stronger justification for the capital requirements and planned allocation of proceeds.
The question shifts from how much to what for
For Speed Medical, the regulatory decision changes the immediate issue facing shareholders.
The company had established the mechanics of the transaction — EGP 600 million in new cash, 3 billion additional shares and tradable subscription rights — but the regulator has challenged the underlying rationale for raising that amount.
That distinction matters for investors because a capital increase of this scale would substantially expand the number of shares outstanding and require existing shareholders either to participate in the subscription or face dilution of their ownership percentages.
Speed Medical will therefore need to demonstrate more clearly where the EGP 600 million would be invested, why that amount is required and how deploying the proceeds would support the company’s operations and future financial performance before attempting to move the transaction forward again.